- WHO applauds Call for Action adopted by South-East Asia countries to accelerate efforts to End TB. More Information
- New MOOC (Massive Open Online Course) on Global Health at the Human Animal Ecosystem Interface launched on World TB Day
Cross-sectoral approaches to Zoonotic TB included as a key focus More Information. Link to MOOC Registration
- To Be Continued - 24 hour music event for World TB Day
This event starts at 00.00 till midnight (GMT+1) on March 24th, 2016. Sounds from Stazione di Topolò/Global Health Incubator across the World and back. More information.
The World Health Organization (WHO) today recommended the use in all settings of a next-generation Xpert® MTB/RIF assay (called Xpert® MTB/RIF Ultra) as a replacement for the current Xpert MTB/RIF® cartridge.
New tuberculosis (TB) ethics guidance, launched today by the World Health Organization (WHO), aims to help ensure that countries implementing the End TB Strategy adhere to sound ethical standards to protect the rights of all those affected.
The new WHO ethics guidance addresses contentious issues such as, the isolation of contagious patients, the rights of TB patients in prison, discriminatory policies against migrants affected by TB, among others. It emphasizes five key ethical obligations for governments, health workers, care providers, nongovernmental organizations, researchers and other stakeholders to:
Ethics Guidance for the Implementation of the End TB Strategy
Fact Sheet on Ethical Issues in TB Prevention, Treatment and Care
In preparing for World TB Day on March 24, the Centers for Disease Control and Prevention’s Division of Tuberculosis Elimination (CDC/DTBE) is pleased to announce additional 2017 World TB Day communication messages and materials that are now available on their website. Materials include:
"Culture of Collaboration" is the theme for the 2017 NTCA National TB Conference. This conference is an annual forum that brings state, local, territorial, and other TB control professionals together to discuss a wide array of clinical, technical, policy, and programmatic TB issues.
This conference will be held on April 18-21 in Atlanta, Georgia, with special meetings on April 18, and post-meetings in the afternoon on Friday, April 21.
Some key topics include:
View Draft Agenda
Topic: The Mycobacteriology Laboratory: Tests, Results, and Clinical Implications
Date: March 17, 2017
Time: 12:00 noon (Central Daylight Time)
A free webinar (400 seats) is being offered by the National TB Nurse Coalition, the nursing section of the National TB Controllers Association (NTCA). 1.2 CEUs are available for nurses. Speakers include:
Registration URL: https://www.pathlms.com/tbcontrollers/courses/4259
On February 27 and 28, a Round Robin was hosted by the Curry International Tuberculosis Center in Oakland, California. All five RTMCCs, along with representatives from the CDC were present. Dr. Temesgen and Jennifer Curran attended from the Mayo Center for Tuberculosis.
Johns Hopkins University and the Medicines Patient Pool (MPP) have signed a license agreement to facilitate the clinical development of the tuberculosis drug, sutezolid. Sutezolid, an oxazolidinone antibiotic in the same class as linezolid, has shown promise in use as a compound in early stage trials to be more potent and less toxic in the treatment of TB.
The CDC has recently published Modules 6 and 8 of the Self-Study Modules in Spanish. These Self-Study Modules on Tuberculosis are a series of educational modules designed to provide information about TB in a self-study format. The series consists of a total of nine modules that are separated into two courses. The first course, Modules 1-5, provides basic information on TB. The second course, Modules 6-9, provides more specific TB programmatic information.
Jointly sponsored by the Regional Training and Medical Consultation Centers, the course "Optimizing Outcomes of Drug-Resistant Tuberculosis in High-Resource, Low-Incidence Settings" will be offered as part of The Union-NAR End TB 2017 Conference in Vancouver, Canada.
This 3-hour training will provide an overview of the medical management and case management of drug-resistant tuberculosis including a discussion of diagnostics, treatment options, special situations, and a panel discussion with clinical and programmatic perspectives on the use of the short course MDR regimen in high-resource, low-incidence settings.
Location: Sheraton Vancouver Wall Centre
Date: February 22
Time: 12:00 p.m. - 3:00 p.m.